About the Study
The GAP Study is evaluating the effectiveness, safety, and tolerability of an investigational drug for Alzheimer's disease. The purpose of this study is to determine whether or not using this investigational drug (IVIg) to treat people with mild-to-moderate Alzheimer's will slow the onset of Alzheimer's symptoms, as compared to a placebo (an inactive substance designed to have no effect on health). All study drugs will be administered in combination with the Alzheimer’s medications that participants are already taking.
Every patient who participates in the GAP Study:
- Must have a study partner (a spouse, child, friend, or other caregiver) who will facilitate the participant's involvement in the study, who can be present at every study visit, and who will monitor the participant throughout the study.
- Will receive study-related care and monitoring throughout the study, as well as study-related drugs, at no cost.
There are possible benefits and risks to study participation that the study doctor can explain to you or the person in your care.
The GAP Study involves:
- An investigational drug, Gammaglobulin (a form of Intravenous Immune Globulin, or IVIg).
- A placebo – a substance that is designed to look like the investigational drug, but that has no effect on health.
